iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) and Invivyd (NASDAQ:IVVD – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.
Profitability
This table compares iTeos Therapeutics and Invivyd’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iTeos Therapeutics | N/A | -20.11% | -17.50% |
| Invivyd | N/A | -155.33% | -114.88% |
Valuation & Earnings
This table compares iTeos Therapeutics and Invivyd”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iTeos Therapeutics | $35.00 million | 8.14 | -$112.64 million | ($3.15) | -2.48 |
| Invivyd | $11.56 million | 4.13 | -$198.64 million | ($1.96) | -0.20 |
Risk & Volatility
iTeos Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for iTeos Therapeutics and Invivyd, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iTeos Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| Invivyd | 0 | 0 | 4 | 1 | 3.20 |
iTeos Therapeutics presently has a consensus target price of $22.25, indicating a potential upside of 185.26%. Invivyd has a consensus target price of $7.89, indicating a potential upside of 1,875.83%. Given Invivyd’s stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than iTeos Therapeutics.
Insider and Institutional Ownership
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 17.9% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
iTeos Therapeutics beats Invivyd on 7 of the 13 factors compared between the two stocks.
About iTeos Therapeutics
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
About Invivyd
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
